Healthcare Royalty, Inc. (HCRX)
| Market Cap | 3.45B |
| Revenue (ttm) | 263.48M |
| Net Income (ttm) | 107.63M |
| Shares Out | 215.50M |
| EPS (ttm) | 0.50 |
| PE Ratio | 32.04 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HCRX
Healthcare Royalty is the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016. We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. Our mission is to facilitate innovation by deploying capital consistently and reliably in products that serve unmet or underserved medical needs. We intend to achieve this mission by expanding our portfolio of approved and pre-approval products using cash flow generated by our exist... [Read more...]
Financial Performance
In 2020, HCRX's revenue was $228.83 million, an increase of 29.06% compared to the previous year's $177.31 million. Earnings were $253.25 million, an increase of 46.77%.
Financial StatementsNews
Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million. Spero will use the proceeds to prepare for the ant...